FDA, Barr to meet next week on morning-after pill

	Tweet

Barr Pharmaceuticals Inc. and the U.S. Food and Drug Administration are scheduled to meet Tuesday to discuss the company’s bid to sell its morning-after contraceptive Plan B without a prescription, the agency said on Wednesday.

“The FDA and Barr Labs will meet on Tuesday in Washington, D.C. to discuss the letter we sent to the company” earlier this week, agency spokeswoman Susan Bro said.

In a letter to Barr on Monday, the FDA said it was taking a new look at proposed sales of Plan B—a set of two pills that can prevent pregnancy if taken within 72 hours of sexual intercourse—without a prescription.

The agency said the pills would be kept behind pharmacy counters and women would need to ask for them. Women younger than 18 still would need a prescription.

The FDA added that it hoped to wrap up Barr’s application, which has lingered at the agency since 2003, within weeks.

The pending decision over Plan B has been controversial, with supporters and critics alike relentlessly lobbying the FDA. It has also held up confirmation of an FDA chief.

Barr shares were up 95 cents or 1.9 percent at $50.16 in morning trade on the New York Stock Exchange.

RELATED STORIES:
US advises firms on better drug safety monitoring   FDA approves AbioCor permanent artificial heart for humanitarian uses   Addictive drugs given to US sleep deprived   G. Bush and Prescription Drugs Prices   UK to save on generic medicines bill   Back to Basics: Aspirin After Knee Surgery   FDA Approves Novartis Hypertension Drug   Brazil plans to break patents on foreign AIDS drugs   Bush signs law banning certain steroid-like drugs   U.S. seizes counterfeit Tamiflu drug   Barr to resubmit contraceptive for FDA approval   FDA nominee stalled over “morning after” pill

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]